Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Additional Cariprazine Trial Could Put Forest In A Better Competitive Position

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA “complete response” letter seeks another trial to better define the most tolerable dose, which could get the atypical antipsychotic to market in a better position than the original dataset.

Advertisement

Related Content

Uphill Climb For Gedeon Richter's Cariprazine After Delayed EU OK
Forest’s Fetzima Will Test Enantiomer Exclusivity Policy Change
APA Update: New Antidepressants Elbow Into Crowded Market
Forest Builds On Viibryd With Levomilnacipran NDA For Its “Middle” Antidepressant
Forest’s Antipsychotic Cariprazine Clears Last Clinical Hurdle To Double NDA Filing In 2012

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel